Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non‐ fumigatus ): A multicentre, non‐interventional registry study

Mycoses ◽  
2021 ◽  
Author(s):  
George R. Thompson ◽  
Julia Garcia‐Diaz ◽  
Marisa H. Miceli ◽  
M. Hong Nguyen ◽  
Luis Ostrosky‐Zeichner ◽  
...  
Keyword(s):  
Invasive Aspergillosis ◽  
Antifungal Therapy ◽  
Registry Study ◽  
Systemic Antifungal Therapy

scholarly journals Migration of dental implants in the maxillary sinus – a putative risk of sinus aspergilossis

2017 ◽  
Vol 63 (4) ◽  
pp. 151-155
Author(s):  
Alexandru Andrei Iliescu ◽  
◽  
Paula Perlea ◽  
Anca Nicoleta Temelcea ◽  
◽  
...  
Keyword(s):  
Invasive Aspergillosis ◽  
Maxillary Sinus ◽  
Dental Implant ◽  
Antifungal Therapy ◽  
Chronic Sinusitis ◽  
Surgical Removal ◽  
Endosseous Implants ◽  
Non Invasive ◽  
Systemic Antifungal Therapy

Sometimes the maxillary endosseous implants may migrate into the maxillary sinus, a quarter of them being recorded in maxillary sinus bone grafts. Less frequent it occurs after the occlusal loading or during the prosthetic abutment insertion. The displacement and retention of a dental implant in maxillary sinus causes a chronic sinusitis. One of such infection might be aspergillosis. Clinically the aspergillosis of maxillary sinus may be non-invasive, invasive or allergic. The treatment of non-invasive aspergillosis in immunocompetent individuals consists in surgical removal of infected fungal mass without a systemic antifungal medication. The invasive aspergillosis which is affecting immunocompromised persons has to be treated both by surgical and long-term systemic antifungal therapy. In allergic form the surgical removal of nasal polyp and recreation of the patency of the maxillary ostium are recommended.

scholarly journals Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis

Mycoses ◽  
2019 ◽  
Vol 62 (10) ◽  
pp. 969-978 ◽  
Author(s):  
Dong‐Gun Lee ◽  
Hye‐Jung Lee ◽  
Jean Li Yan ◽  
Stephen Sheng‐Fong Lin ◽  
Jalal A. Aram
Keyword(s):  
Invasive Aspergillosis ◽  
Antifungal Therapy ◽  
Efficacy And Safety ◽  
Haematological Patients

scholarly journals Sequential or Combination Antifungal Therapy with Voriconazole and Liposomal Amphotericin B in a Guinea Pig Model of Invasive Aspergillosis

2006 ◽  
Vol 50 (4) ◽  
pp. 1567-1569 ◽  
Author(s):  
William R. Kirkpatrick ◽  
Brent J. Coco ◽  
Thomas F. Patterson
Keyword(s):  
Guinea Pig ◽  
Invasive Aspergillosis ◽  
Amphotericin B ◽  
Antifungal Therapy ◽  
Liposomal Amphotericin ◽  
Pig Model ◽  
Liposomal Amphotericin B ◽  
Guinea Pig Model

ABSTRACT We evaluated combinations of voriconazole (VRC) and liposomal amphotericin B (L-AMB) in a guinea pig invasive aspergillosis model. Simultaneous VRC and L-AMB was most effective, although VRC monotherapy was also effective. These regimens as well as sequential L-AMB followed by VRC were more effective than L-AMB alone or VRC followed by L-AMB.

Use of Antifungal Therapy in Hospitalized Patients II. Results after the Marketing of Fluconazole

1994 ◽  
Vol 28 (2) ◽  
pp. 261-270 ◽  
Author(s):  
Thaddeus H. Grasela ◽  
Mary T. Pasko ◽  
S. Diane Goodwin ◽  
Cynthia A. Walawander ◽  
Nicole Blackwelder ◽  
...  
Keyword(s):  
Phase I ◽  
Amphotericin B ◽  
Phase Ii ◽  
Antifungal Therapy ◽  
Antifungal Agent ◽  
Phase I Study ◽  
Antifungal Agents ◽  
Hospitalized Patients ◽  
Prescribing Patterns ◽  
Systemic Antifungal Therapy

OBJECTIVE: To evaluatethe prescribing patternsof antifungal agents in the hospital setting after the introduction of fluconazole, a new broad-spectrum bis-triazole antifungal agent. Also comparedare the prescribing patterns of antifungal agents prior to (phase I) and following (phase II) fluconazole marketing. DESIGN: A prospective cohort of hospitalized patients prescribed topical or systemic antifungal agents. Data were collected from December 1990 to April 1991. SETTING: Fifty-seven hospitals ranging in size from 100 to more than 500 beds. Sixty-three percentare affiliated with medical schools. PATIENTS: Participating pharmacists consecutively identified 15 patients receiving systemic antifungal therapy and 5 patients receiving topical antifungal therapy. INTERVENTIONS: Observational data on patient antifungal therapy, risk factors for fungal infections, comorbidities, concurrent medications, and culture data were collected. MEASURES: Differences in prescribing patterns before and after the marketing of fluconazole were assessed using t-tests and chi-square tests. RESULTS: Of 818 patients studied, 615 (75.2 percent) received systemic antifungal therapy. Five hundred forty-six patients received a single antifungal agent; 348 (63.7 percent) received fluconazole, 105 (19.2 percent) received ketoconazole, 92 (16.8 percent) received amphotericin B, and 1 (0.2 percent) received flucytosine. Sixty-nine patients received two or more systemic agents either concurrently or consecutively. The use of parenteral amphotericin B, alone or in combination with flucytosine and/or an azole, declined from 56.8 percent in the phase I study to 24.2 percent in the current study. The use of parenteral therapy also declined from 56.8 to 40.2 percent. Ketoconazole was used in more than 90 percent of the oral and esophageal infections in the phase I study, but its use declined to only 33 percent in this study. Fluconazole was used most frequently across all sites of presumed or documented infections, with the exception of fungemia. Of the presumed or proven systemic or blood infections, amphotericin B was used alone or in combination in 48.4 percent of the patients and fluconazole was used exclusively in 39.0 percent of the patients. Fluconazole was used more often than amphotericin B (22 vs. 3 patients, respectively) for prophylaxis of systemic infections. The overall use of antifungal prophylaxis also increased from the phase I (9.5 percent) to phase II (13.7 percent). CONCLUSIONS: The introduction of fluconazole had a major impact on the prescribing patterns of antifungal therapy. Although amphotericin B remained the preferred agent for treatment of suspected or proven systemic, central nervous system, or blood infections, use of fluconazole for these indications approached nearly 40 percent. Further studies are needed to address the role of fluconazole in the prophylaxis and treatment of systemic mycoses.

Sign in / Sign up

Export Citation Format

Share Document